Treatment of chronic urticaria with omalizumab: the experience of Hospital de Braga

Introduction: Omalizumab is approved for the treatment of severe chronic spontaneous urticaria (CSU), unresponsive to quadruple doses of nonsedative H1 antihistamine. Few data are available to help predict the response to omalizumab in the Portuguese population. Objective: Characterize the populatio...

Fuld beskrivelse

Saved in:
Bibliografiske detaljer
Main Authors: Ana G. Lopes (Author), Marianlie Navarro (Author), Carmem Botelho (Author), Maria J. Guimarães (Author), Catarina Cerqueira (Author), Joana Gomes (Author), Celeste Brito (Author)
Format: Bog
Udgivet: Sociedade Portuguesa de Dermatologia e Venereologia, 2022-10-01T00:00:00Z.
Fag:
Online adgang:Connect to this object online.
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!